23 November 2022 - Report will be subject of CTAF meeting in June 2023; draft scoping document open to public comment until 15 December 2022.
The ICER announced today that it will assess the comparative clinical effectiveness and value of exagamglogene autotemcel (“exa-cel”, Vertex Pharmaceuticals and CRISPR Therapeutics) and lovotibeglogene autotemcel (“lovo-cel”, bluebird bio) for sickle cell disease.